Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema
Comparative Evaluation of Polarized Dermoscopy and Ultraviolet-Induced Fluorescence Dermoscopy in the Differential Diagnosis of Palmoplantar Psoriasis and Palmoplantar Eczema
Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Because these conditions can look alike, distinguishing between them in routine clinical practice may be difficult.
This prospective, single-center observational study was designed to compare polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in adult patients with palmoplantar psoriasis and palmoplantar eczema. A total of 81 patients aged 18 years and older were included: 41 patients with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis and 40 patients with palmoplantar eczema.
Dermoscopic and UVFD images were evaluated to identify vascular, scaling, surface, and fluorescence-related features that may help differentiate palmoplantar psoriasis from palmoplantar eczema. The study aims to assess whether these non-invasive imaging methods can provide additional diagnostic clues to support clinical evaluation.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This prospective, single-center, observational comparative study was designed to evaluate polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema.
Adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were enrolled. Patients with recent topical or systemic treatment, positive fungal examination, palmoplantar pustulosis, other confounding palmoplantar dermatoses, malignancy or immunosuppressive conditions, pregnancy, lactation, non-specific histopathological findings, or histopathological findings inconsistent with the clinical diagnosis were excluded.
Demographic and clinical characteristics, lesion localization, symptom profile, relevant dermatological history, nail involvement, and disease severity parameters were recorded. Standardized polarized dermoscopic and UVFD images were obtained using a handheld dermoscope (DermLite DL5, 3Gen Inc., San Juan Capistrano, CA, USA). Imaging was performed under standardized conditions, and predefined dermoscopic and UVFD parameters relevant to inflammatory palmoplantar dermatoses were systematically evaluated.
In polarized dermoscopy, vascular morphology and distribution, scale color and distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales were assessed. In UVFD, scale distribution, scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci were evaluated. Image assessments were performed by independent dermatologists blinded to the clinical diagnosis.
The main objective of the study is to compare polarized dermoscopic and UVFD findings between palmoplantar psoriasis and palmoplantar eczema and to identify features that may support the clinical differentiation of these overlapping palmoplantar dermatoses. The study does not assign any treatment or intervention; all imaging procedures are non-invasive and performed for observational diagnostic evaluation.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Istanbul
-
Istanbul, Istanbul, Turchia (Türkiye), 34000
- Istanbul Training and Research Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age 18 years or older.
- Clinical diagnosis of palmoplantar psoriasis or palmoplantar eczema involving the palms and/or soles.
- For the palmoplantar psoriasis group: presence of sharply demarcated erythematous and scaly plaques on the palms and/or soles, with diagnosis confirmed clinically and/or histopathologically.
- In clinically uncertain palmoplantar psoriasis cases, at least one supporting feature such as psoriatic lesions outside the palmoplantar area, psoriatic nail involvement, psoriatic arthritis, personal history of psoriasis, or family history of psoriasis.
- For the palmoplantar eczema group: presence of chronic or recurrent palmoplantar eczema with hyperkeratotic and/or fissured palmoplantar plaques, with diagnosis confirmed clinically and/or histopathologically.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Age younger than 18 years.
- Presence of another palmoplantar dermatosis that may interfere with the diagnosis of palmoplantar psoriasis or palmoplantar eczema.
- Histopathological findings inconsistent with the clinical diagnosis, when histopathological examination was performed.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Palmoplantar Psoriasis
Patients with clinically and/or histopathologically confirmed palmoplantar psoriasis
|
|
Palmoplantar Eczema
Patients with clinically and/or histopathologically confirmed palmoplantar eczema
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Findings on the Predefined Polarized Dermoscopic Feature Checklist Assessed Using DermLite DL5
Lasso di tempo: At baseline / single study visit
|
Name of measurement: Predefined Polarized Dermoscopic Feature Checklist. Measurement tool: standardized polarized dermoscopic images obtained with a DermLite DL5 handheld dermoscope. Unit of measure: percentage of participants (%). Standardized polarized dermoscopic images will be assessed by blinded independent dermatologists using the checklist. The checklist includes vascular morphology, vascular distribution, scale color, scale distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales. The percentage of participants with each finding will be reported separately for the palmoplantar psoriasis and palmoplantar eczema groups. |
At baseline / single study visit
|
|
Percentage of Participants With Each Predefined Ultraviolet-Induced Fluorescence Dermoscopy Feature Assessed by DermLite DL5
Lasso di tempo: At baseline / single study visit
|
Unit of measure: percentage of participants (%).
Measurement tool: standardized ultraviolet-induced fluorescence dermoscopy (UVFD) images obtained with a DermLite DL5 handheld dermoscope and assessed by blinded independent dermatologists using a predefined UVFD feature checklist.
The checklist includes UVFD scale distribution, UVFD scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci.
The percentage of participants with each feature will be reported and compared between the palmoplantar psoriasis and palmoplantar eczema groups.
|
At baseline / single study visit
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cohen's Kappa Coefficient for Interobserver Agreement in Binary and Nominal Dermoscopic and UVFD Feature Assessment
Lasso di tempo: At baseline / single study visit
|
Name of measurement: Cohen's kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: Cohen's kappa coefficient. Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Cohen's kappa coefficient will be calculated separately for binary and nominal categorical checklist findings to evaluate interobserver agreement. |
At baseline / single study visit
|
|
Quadratic Weighted Kappa Coefficient for Interobserver Agreement in Ordinal Dermoscopic and UVFD Feature Assessment
Lasso di tempo: At baseline / single study visit
|
Name of measurement: quadratic weighted kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: quadratic weighted kappa coefficient. Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Quadratic weighted kappa coefficient will be calculated separately for ordinal checklist findings to evaluate interobserver agreement. |
At baseline / single study visit
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2011-KAEK-50-263
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .